Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin

Pharmaceutical Research

Volumn 16, Issue 6, 1999, Pages 916-923

  Tsutsumi, Yasuhiro ^a   Maruyama, Toru ^a   Takadate, Akira ^b   Goto, Masafumi ^a   Matsunaga, Hiroshi ^c   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^c Lederle (Japan) Ltd   (Japan)

Author keywords

Bilirubin; Dicarboxylate; Electrostatic interaction; Human serum albumin; Uremic toxin

Indexed keywords

BILIRUBIN; DICARBOXYLIC ACID; HUMAN SERUM ALBUMIN; UREMIC TOXIN;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; ELECTRICITY; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

BILIRUBIN; BINDING SITES; BINDING, COMPETITIVE; DICARBOXYLIC ACIDS; FURANS; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; PHENYLBUTAZONE; PROPIONIC ACIDS; PROTEIN CONFORMATION; SERUM ALBUMIN; WARFARIN;

EID: 0033020562     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018842506896     Document Type: Article

References (30)

1. 1. H. Mabuchi and H. Nakahashi. Isolation and characterization of an endogenous drug-binding inhibitor present in uremic serum. Nephron. 44:277-81 (1986).
2. 2. H. Mabuchi, H. Nakahashi, T. Hamajima, I. Aikawa, and T. Oka. The effect of renal transplantation on a major endogenous ligand retained in uremic serum. Am. J. Kidney Dis. 13:49-54 (1989).
3. 3. T. Sakai, A, Takadate, and M. Otagiri. Characterization of binding site of uremic toxins on human serum albumin. Biol. Pharm. Bull. 18:1755-61 (1995).
4. 4. J. J. McTigue, S. J. Henderson, and W. E. Lindup. Excretion of the uraemic metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human urine. Nephron. 55:214-5 (1990).
5. 5. M. G. Costigan, C. A. Callaghan, and W. E. Lindup. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron. 73:169-73 (1996).
6. 6. C-F. Lim, R. Docter, E. P. Krenning, H. van Toor, B. Bernard, M. de Jong, and G. Hennemann. Transport of thyroxine into cultured hepatocytes: effects of mild non-thyroidal illness and calorie restriction in obese subjects. Clin. Endocrinol. 40:79-85 (1994).
7. 7. S. J. Henderson and W. E. Lindup. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J. Pharmacol. Exp. Ther. 263:54-60 (1992).
8. 8. R. Brodersen. Bilirubin. Solubility and interaction with albumin and phospholipid. J. Biol. Chem. 254:2364-2369 (1979).
9. 9. K. J. Fehske, W. E. Muller̀, and U. Wollert. The location of drug binding sites in human serum albumin. Biochem. Pharmacol. 30:687-692 (1981).
10. 10. J. M. B. Octaaf, L. M. V. Eugene, C. I. B. Jan Paul, J. E. F. Marcel, W. Jaap, and H. M. J. Lambert. Location and characterization of the suramin binding sites of human serum albumin. Biochem. Pharmacol. 40:1595-1599 (1990).
11. 11. R. F. Chen. Removal of fatty acids from serum albuminby charcoal treatment. J. Biol. Chem. 242:173-181 (1967).
12. 12. M. G. Costigan, T. L. Gilchrist, and W. E. Lindup. Synthesis and physicochemical properties of the furan dicarboxylic acid, 3-carboxy-4-methyl-5-propyl-2-furanpiopanoic acid, an inhibitor of plasma protein binding in uraemia. J. Pharm. Pharmacol. 48:635 40 (1996).
13. 13. J. Pfordt, H. Thoma, and G. Spiteller. Identification, structure elucidation, and synthesis of previously unknown urofuranic acids in human blood. Liebigs Ann. Chem. 2298-2308 (1981).
14. 14. R. Brodersen. Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J. Clin. Invest. 54:1353-64 (1974).
15. 15. R. L. Levine. Fluorescence-quenching studies of the binding of bilirubin to albumin. Clin. Chem. 23:2292-301 (1977).
16. 16. G. Sudlow, D. J. Birkett, and D. N. Wade. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11:824-32 (1975).
17. 17. K. J. Fehske, W. E. Muller, and U. Wollert. The modification of the lone tryptophan residue in human serum albumin by 2-hydroxy-5-nitrobenzyl bromide. Characterization of the modified protein and the binding of L-tryptophan and benzodiazepines to the tryptophan-modified albumin. Hoppe Seylers Zeitschrift fur Physiologische Chemie. 359:709-17 (1978).
18. 18. K. J. Fehske, W. E. Muller, and U. Wollert. A highly reactive tyrosine residue as part of the indole and benzodiazepine binding site of human scrum albumin, Biochim. Biophys. Acta 577:346-59 (1979).
19. 19. A. D. Gounaris and G. E. Perlmann. Succinylation of pepsinogen. J. Biol. Chem. 242:2739-45 (1967).
20. 20. R. Haynes, D. T. Osuga, and R. E. Feeney. Modification of amino groups in inhibitors of proteolytic enzymes. Biochemistry 6:541-7 (1967).
21. 21. J. L. Roosemont. Reaction of histidine residues in proteins with diethylpyrocarbonate: differential molar absorptivities and reactivities. Anal. Biochem. 88:314-20 (1978).
22. 22. H. Aki and M. Yamamoto. Thermodynamic characterization of drug binding to human serum albumin by isothermal titration microcalorimetry. J. Pharm. Sci. 83:1712-6 (1994).
23. 23. C. B. Beide, B. S. Hudson, R. D. Simoni, and L. A. Sklar. Human serum albumin. Spectroscopic studies of binding and proximity relationships for fatty acids and bilirubin. J. Biol. Chem. 254:391-400 (1979).
24. 24. D. A. Lightner, D. L. Holmes, and A. F. McDonagh. On the acid dissociation constants of bilirubin and biliverdin. pKa values from 13C NMR spectroscopy. J. Biol. Chem. 271:2397-405 (1996).
25. 25. C. Jacobsen. Lysine residue 240 of human serum albumin is involved in high-affinity binding of bilirubin. Biochem. J. 171:453-459 (1978).
26. 26. S. Curry, H. Mandelkow, P. Brick, and N. Franks. Crystal structure of human serum albumin completed with fatty acid reveals an asymmetric distribution of binding sites. Nature Structural Biology 5:827-835 (1998).
27. 27. N. Roosdorp, B. Wann, and I. Sjoholm. Correlation between arginyl residue modification and benzodiazepine binding to human serum albumin. J. Biol. Chem. 252:3876-3880 (1977).
28. 28. I. Sjoholm, B. Ekman, A. Kober, I. Ljungstedt-Pahlman, B. Seiving, and T. Sjodin. Binding of drug to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol. Pharmacol. 16:767-777 (1979).
29. 29. J. Jacobsen and R. Brodersen. Albumin-bilirubin binding mechanism. J. Biol. Chem. 258:6319-26 (1983).
30. 30. J. H. Tonsgard and S. C. Meredith. Characterization of the binding sites for dicarboxylic acids on bovine serum albumin. Biochem. J. 276:569-575 (1991).